Abstract
In this chapter an attempt will be made to define the significance and role of hormonal treatment of breast cancer. This type of treatment can no longer be used alone and it should be considered in the general perspective of a resolute attempt to utilize all existing biological and pharmacologic information available for the improvement of patient care. This is not a complete review of the subject but rather a chapter in the nomenclature and critical evaluation of methods of treatment now available to a “task force” with ambitious therapeutic aims. Recent progress in the treatment of Hodgkin’s disease, leukemia, osteogenic sarcoma, and of other tumor types has provided the encouragement for a renewed and concerted attack on breast cancer, a disease which affects 1 out of every 20 women and has a mortality rate of probably over 75% which has practically remained unchanged in the last 50 years.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
BULBROOK, R.D., GREENWOOD, F.C., HAYWARD, J.L.: Selection of breast cancer patients for adrenalectomy or hypophysectomy by determination of urinary 17-hydroxycorticosteroids and aetiocholanolone. Lancet I, 1154–1157 (1960).
Cooperative Breast Cancer Group: Testosterone propionate therapy in breast cancer. J. Amer. med. Ass. 188, 1069–1072 (1964).
Cooperative Breast Cancer Group: Progress report: results of studies by the Cooperative Breast Cancer Group 1959–60. Cancer Chemother. Rep. 11, 109–141 (1961).
Council on Drugs: Androgens and estrogens in the treatment of disseminated mammary carcinoma. J. Amer. med. Ass. 172, 1271–1283 (1960).
FRACCHIA, A.A., FARROW, J.H., MILLER, T.R., TOLLEFSEN, R.H., GREENBERG, H.J., KNAPPER, W.H.: Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surg. Gynec. Obstet. 133, 241–246 (1971).
Groupe Europeen du Cancer du Sein: Le traitement hormonal du cancer du sein en phase avancée. Comparaison entre le propionate de testosterone et la combinaison propionate de testosterone-delta-I-testololactone. Rev. franç. Et. clin. biol. 9, 88–90 (1964).
HORWITZ, K.B., MCGUIRE, W.L., PEARSON, O.H., SEGALOFF, A.: Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189, 726–727 (1975).
LECLERCQ, G., HEUSON, J.C., DEBOEL, M.C., MATTHEIEM, W.H.: Estrogen receptors in breast cancer: a changing concept. Brit. med. J. 1, 185–189 (1975).
MCGUIRE, W.L., CARBONE, P.P., VOLLMER, E.P.: Estrogen Receptors in Human Breast Cancer. New York: Raven Press, 1975.
STAQUET, M., TAGNON, M., KENIS, Y., BONADONNA, G., CARTER, S.K., SOKAL, G., TROUET, A., GHIONE, M., PRAGA, C., LENAZ, L., KARIM, O.S.: EORTC International Symposium. Adriamycin Review. Medikon, Ghent: European Press, 1974.
STOLL, B.A.: Mammary Cancer and Neuroendocrine Therapy. London: Butterworths, 1974.
TAGNON, H.J.: Clinical results with hormones in disseminated mammary cancer. In: Chemotherapy of Cancer. PLATTNER, P.A. (ed.). New York: Elsevier, 1964.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1976 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Tagnon, H.J. (1976). The Role of Hormones in the Modern Treatment of Advanced Breast Cancer. In: St-Arneault, G., Band, P., Israël, L. (eds) Breast Cancer. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 57. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81043-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-81043-5_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81045-9
Online ISBN: 978-3-642-81043-5
eBook Packages: Springer Book Archive